期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

浸润性膀胱尿路上皮癌的新辅助化疗进展 被引量：6

原文传递
导出
摘要 每年新诊断的膀胱肿瘤中浸润性尿路上皮癌或转移性癌占25％，20％～30％的非浸润性尿路上皮癌术后也将发展为浸润性或转移性癌。即便对浸润性尿路上皮癌进行膀胱根治性切除和（或）放疗，50％仍会出现转移，病变局限于膀胱者5年生存率为75％～90％，发生局部外侵者45％～60％，
作者 闫伟 王伟 陈山
机构地区 首都医科大学附属北京同仁医院泌尿外科
出处 《中华泌尿外科杂志》 CAS CSCD 北大核心 2010年第1期67-69,共3页 Chinese Journal of Urology
关键词 膀胱尿路上皮癌 浸润性 化疗进展 转移性癌 根治性切除 5年生存率 膀胱肿瘤 局部外侵
分类号 R737.14 [医药卫生—肿瘤] R737.9 [医药卫生—临床医学]
  • 相关文献

参考文献23

  • 1Stenzl A, Cowan NC, De Santis M, et al. The updated EAU guidelines on musele-invasive and metastatic bladder cancer. Eur Urol, 2009, 55: 815- 825. 被引量：1
  • 2那彦群主编..中国泌尿外科疾病诊断治疗指南 2007版[M].北京:人民卫生出版社,2007:401.
  • 3Herr HW, Dotan Z, Donat SM, et al. Defining optimal therapy for muscle invasive bladder cancer. J Urol, 2007, 177: 437-443. 被引量：1
  • 4Donat SM, Shabsigh A, Savage C, et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high- volume tertiary cancer center experience. Eur Urol, 2009, 55: 176-185. 被引量：1
  • 5Teramukai S, Nishiyama H, Matsui Y, et al. Evaluation for surrogacy of end points by using data from observational studies: tumor downstaging for evaluating neoadiuvant chemotherapy in invasive bladder cancer. Clin Cancer Res, 2006, 12 : 139-143. 被引量：1
  • 6Herr HW, Donat SM, Bajorin DF. Postcbemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol, 2001, 165.. 811-814. 被引量：1
  • 7Stein JP. Contemporary concepts of radical cysteetomy and the treatment of bladder cancer. J Urot, 2003, 169: 116-117. 被引量：1
  • 8Millikan R, Dinney C, Swanson D, et al. Integrated therapy for locally advanced bladder cancer: Final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol, 2001, 19: 4005-4013. 被引量：1
  • 9Dash A, Pettus JA, Bochner BH et al. Efficacy of neo-adjuvant gemeitabine plus cisplatin (GC) in muscleinvasive urothelial cancer (UC). ASCO Annual Meeting Proceedings Part 1. J Clin Oncol, 2007, 25: 5077. 被引量：1
  • 10Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase Ⅲ intergroup study of cisp latin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a Cooperative Group study. J Clin Oncol, 1997, 15: 2564-2569. 被引量：1

二级参考文献4

  • 1Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase Ⅲ intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a Cooperative Group study[ J]. J Clin Oncol, 1997, 15 (12) : 2564-2569. 被引量：1
  • 2Moore M J, Tannock IF, Scott Ernst D, et al. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer [J]. J Clin Oncol, 1997, 15(12) : 3441-3445. 被引量：1
  • 3Barocas DA, Clark PE. Bladder cancer[ J ]. Curr Opin Oncol, 2008, 20(3) : 307-314. 被引量：1
  • 4vonder Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer [ J ]. J Clin Oncol, 2005, 23 (21) :4602 - 4608. 被引量：1

共引文献6

同被引文献77

  • 1陈从波,王晓康,姚启盛,陈立新,杨勇.经尿道膀胱肿瘤电切术联合经尿道前列腺电汽化术治疗膀胱癌并前列腺增生症[J].中国内镜杂志,2005,11(1):13-14. 被引量：14
  • 2刘智惠,姜涛,钟守斌,王涛,刘方军,刘振先.三维适形放射治疗膀胱癌的效果[J].实用医药杂志,2006,23(8):923-924. 被引量：6
  • 3李远伟,赵晓昆,蒋宏毅,王荫槐,刘任.Studer原位尿流改道在女性膀胱癌治疗中的应用[J].中华泌尿外科杂志,2007,28(4):264-267. 被引量：4
  • 4Stein JP, Skinner DG. Surgical atlas. Radical cystectomy. BJUInt, 2004, 94: 197-221. 被引量：1
  • 5Stein JP, Quek ML, Skinner DG. Lymphadenectomy for invasivebladder cancer. II . Technical aspects and prognostic factors.BJU Int, 2006,97: 232-237. 被引量：1
  • 6Merseburger AS, Matuschek I,Kuczyk MA. Bladder preservingstrategies for muscle-invasive bladder cancer. Cuit Opin Urol,2008, 18: 513-518. 被引量：1
  • 7Solsona E , Climent MA, Lborra I,et al. Bladder preservation inselected patients with muscle-invasive bladder cancer by completetransurethral resection of the bladder plus systemic chemothera-py :long-term follow-up of a phase 2 nonrandomized comparativetrial with radical cystectomy. Eur Urol, 2009,55: 911-919. 被引量：1
  • 8Herr HW,Bajorin DF, Scher HI. Neoadjuvant chemotherapyand bladder-sparing surgery for invasive bladder cancer: ten-yearoutcome. J Clin Oncol, 1998 , 16: 1298-1301. 被引量：1
  • 9Splinter T, Denis L. Restaing procedures, criteria of response,and relationship between pathological response and survival.Semin Oncol, 1990 , 17: 606-612. 被引量：1
  • 10Herr HW. Transurethral resection of muscle-invasive bladdercancer: 10-year outcome. J Clin Oncol, 2001,19: 89-93. 被引量：1

引证文献6

二级引证文献72

中华泌尿外科杂志
2010年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部